The ASTCT Pharmacy SIG November 2025 Journal Club will air on Wednesday, November 19 at 2 p.m. CT/3 p.m. ET. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the November Journal Club session, Drs. Donovan and Santos will present two articles related to:

• PTCy-based GVHD Prophylaxis after mismatched unrelated donor peripheral blood stem cell transplant
• CAR-T Therapy for Richter Transformation

Presenters & Articles:

Daniel Donovan, PharmD

PGY-2 Pharmacy Resident

MD Anderson Cancer Center

Article: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Cheyenne Santos, PharmD

PGY-2 Pharmacy Resident

Oregon Health & Sciences University

Article: Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Review current evidence and clinical practices for graft-versus-host disease (GVHD) prophylaxis following hematopoietic stem cell transplantation (HSCT)
• Evaluate the utility and clinical significance of PTCy-based prophylaxis in mismatched unrelated donor (MMUD) transplantation among various conditioning regimens
• Review current treatment recommendations for relapsed refractory Richer transformation
• Evaluate the safety and efficacy of anti-CD19 CAR-T therapy for patients with relapsed refractory Richter transformation 
• Summarize the role of anti-CD19 CAR-T therapy for patients with relapsed refractory Richter transformation

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

The full accreditation information for this session will be available soon.

The Pharmacy HCT Core Topics Live Session will air on Wednesday, November 5 from 2:00 - 3:00 p.m. CST. This live session will focus on two core topics in the field - GVHD and Infectious Complications. The faculty below will briefly present slides on their topic, and then answer questions and share their experiences from their institutions. The target audience is PGY2 Oncology Pharmacy Residents, but is open to all trainees or other practitioners interested in HCT and cellular therapy. This webinar will be recorded and there is no CE offered for attending this session.

Live Session Faculty:

GVHD

Catie Cash, PharmD, BCOP

Clinical Oncology Pharmacist, Adult Bone Marrow Transplant and Cellular Therapy

Duke University Hospital 

Elizabeth DiMaggio, PharmD, BCOP

Clinical Pharmacist, Blood and Marrow Transplantation and Cellular Immunotherapy

Moffitt Cancer Center 

Infectious Complications 

Aaron Cumpston, PharmD, BCOP

Pharmacy Clinical Specialist, TCT/HM

West Virginia University Medicine 

Terri Lynn Shigle, PharmD, BCOP

Clinical Pharmacy Specialist

MD Anderson Cancer Center

Please join us for the ASTCT Pharmacy SIG Career Search Panel on Wednesday, October 29th at 2 p.m. CDT/ 3 p.m. EDT.  This live session will feature a panel of pharmacists in traditional and non-traditional oncology pharmacy roles discussing their respective career paths. The goal of this session is to assist new and current pharmacy practitioners with navigating their career journeys by allowing them to engage with oncology pharmacists working in a variety of practice settings. This event is open to all healthcare professionals who are members and non-members of ASTCT. We hope to see you on October 29th!  

Panelists: 

• Marin Abousaud, PharmD, BCOP - Director of Medical Education, Hematology & Oncology 
• Kelley Carlstrom, PharmD, BCOP - CEO of KelleyDPharmD
• Amber Clemmons, PharmD, BCOP, FHOPA - Clinical Professor University of Georgia College of Pharmacy, BMT Clinical Pharmacist at Wellstar-MCG Health, PGY2 Oncology Residency Director UGA/Wellstar-MCG Health
• LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT - Atrium Health Wake Forest Baptist PGY2 Oncology Residency Program Director, Director of Pharmacy, Clinical Oncology at Atrium Health, Pharmacy Clinical Specialist in Stem Cell Transplant and Cellular Therapy  
• Julianna Merten, PharmD, BCPS, BCOP - Senior Manager, US Medical Affairs Training and Excellence, Jazz Pharmaceuticals
• Melisa Stricherz, PharmD, BCOP - Associate Director of Strategy & Development at Jazz Pharmaceuticals     

Join us on Tuesday, September 30 at 11 a.m. CT / 12 p.m. ET for the webinar, “The Role of RFIs in the Payer-Provider Relationship.”

This session will demystify the role of the Request for Information (RFI) in Center of Excellence (COE) participation. As we prepare for upcoming changes in 2026, the webinar will provide clarity on the purpose and evolving standards of the RFI, its connection to payer-provider relationships, and its integration with CIBMTR data.

Our speakers will discuss:

• The intent behind RFI standardization and its impact on COE participation
• Key updates to the current RFI and what to expect in 2026
• How to navigate RFI documents, source and validate data, and address common challenges
• Strategies for handling unique or emerging therapies that may not fit standard definitions

This webinar is intended for data coordinators, program managers, and anyone involved in RFI completion, but is open to all ASTCT members and non-members.

Speakers:

• Claire White, MSN, RN - Access & Policy Specialist, Children's Hospital of Philadelphia
• Victoria Collier, RN, BSN - Quality Program Manager, Children's Hospital of Philadelphia

The ASTCT Pharmacy SIG September 2025 Journal Club will air on Wednesday, September 24 at 2 p.m. CT/3 p.m. ET. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the September Journal Club session, Drs. Yi and Trinh will present two articles related to:

• Enhanced CAR T-cell therapy for lymphoma after previous failure
• Linvoseltamab for the treatment of relapsed/refractory multiple myeloma 

Presenters & Articles:

Ha Nguyen Trinh, PharmD

PGY-2 Pharmacy Resident

Emory Healthcare | Winship Cancer Institute 

Article: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure

Hannah Yi, PharmD

PGY-2 Pharmacy Resident

UT Southwestern Medical Center

Article: Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Review the four commercially available anti-CD19 CAR T-cell products and their place in current guideline of CD19+ B-cell lymphomas
• Evaluate the safety and efficacy of the enhanced CART T-cell therapy (huCART19-IL18) in phase 1 trial
• Discuss the clinical implications of huCART19-IL18 for relapsed CD19+ B-cell lymphomas after prior anti-CD19 CAR T-cell therapy
• Describe the current treatment landscape of relapsed/refractory multiple myeloma (RRMM)
• Analyze the efficacy outcomes and safety profile of linvoseltamab in the LINKER-MM1 trial
• Evaluate the potential clinical impact of linvoseltamab in the treatment of RRMM

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

The full accreditation information for this session can be found HERE. 

This interactive webinar will highlight key research abstracts featured at the 2025 Tandem Meetings of ASTCT and CIBMTR. It features posters that were selected for the Palliative Care SIG Poster Walk and emphasizes these interprofessional authors and their research posters:

Richard Newcomb, MD, Massachusetts General Hospital

• "Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation" 

Daniel Trotier, MD, The Ohio State University

• “Has Palliative Care and Hospice Utilization Changed for Patients with Relapsed/Refractory Large B-Cell Lymphoma in the Era of CAR-T?"

Alexi Vasbinder, PhD, RN, University of Washington School of Nursing

• "Associations between Symptom Severity and Distress with Functional Status after Allogeneic Hematopoietic Cell Transplantation."

This webinar discusses the role of non-Aspergillus mold infections (NAIMIs) in hematopoietic cell transplantation (HCT) recipients. Upon completion of this activity, attendees will gain knowledge on identifying NAIMIs, understanding risk factors, and recognizing clinical presentations. The session covers current diagnostic methods, treatment options, and preventive strategies, including antifungal prophylaxis and infection control measures. Participants will also learn about emerging therapies and the impact of these infections on patient outcomes.

Presenter: 

Abby P. Douglas, Department of Infectious Diseases, National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Host: Sanjeet Dadwal, MD, Professor of Medicine and Chief, Division of Infectious Disease, City of Hope National Medical Center, Los Angeles, California

The Pharmacy HCT Core Topics Live Session will air on Wednesday, September 3 from 2:00 - 3:00 p.m. CDT. This live session will focus on two core topics in the field - Conditioning Regimens & Immunosuppression Management. The faculty below will briefly present slides on their topic, and then answer questions and share their experiences from their institutions. The target audience is PGY2 Oncology Pharmacy Residents, but is open to all trainees or other practitioners interested in HCT and cellular therapy. This webinar will be recorded and there is no CE offered for attending this session.

Live Session Faculty:

Conditioning Regimens

Binni Kunvarjee, PharmD, BCOP

Clinical Pharmacy Specialist

Memorial Sloan Kettering Cancer Center

Jessica Lewis-Gonzalez, PharmD, BCOP

Oncology Clinical Pharmacy Specialist

The University of New Mexico

Immunosuppression Management

Elizabeth Eubanks, PharmD, MPH, BCPS, BCOP, CPP

Clinical Oncology Pharmacist, Adult Bone Marrow Transplant & Cellular Therapy

Duke University Medical Center

Vinita Pai, PharmD, MS, BCPPS

Associate Professor - Clinical 

College of Pharmacy, Division of Pharmacy Practice and Sciences

The Ohio State University

Join the APP SIG on Thursday, August 28 at 2 p.m. CDT for the Strategies for Difficult Conversations webinar. Providers caring for patients receiving transplants and cellular therapy are often required to deliver a range of serious news. This may include information about complications of therapy, changes to the underlying disease status, and notification that disease-directed interventions are no longer available. Attendees of this presentation will review the current literature related to communication with patients and families and discuss common practices and barriers observed. Strategies for effective communication where honest news is delivered with compassion will be described. There will be an opportunity to utilize these new skills by practicing delivering serious news guided by one of the strategies discussed.

This webinar is open to all ASTCT members and non-members. There will not be any continuing education offered for attending this webinar.

Speaker:

Jessica Spruit, DNP; University of Michigan

Join ASTCT Director of Government Relations, Molly Ford, and Reimbursement and Policy Advisors from Nimitt Consulting for a webinar on Medicare rule updates on August 20 at 12 p.m. CDT/1 p.m. EDT.

This webinar will cover:

• FY 2026 Inpatient Prospective Payment System (IPPS) Final Rule:
  • Final payment rates and policies for key MS-DRGs for Stem Cell Transplant MS-DRGs (014, 016 and 017) and CAR-T and Other Immunotherapies (MS-DRG 018)
  • Discussion of CMS’ final decisions on relevant New Technology Add-on Payments (NTAP) for cell and gene therapy products
  • Final fixed outlier loss threshold and market basket update amounts
• CY 2026 Outpatient Prospective Payment System (OPPS) Proposed Rule:
  • Major payment and policy proposals related to cell and gene therapies
  • Other major proposals likely to impact hospitals if finalized
• CY 2026 Medicare Physician Fee Schedule (MPFS) Proposed Rule:
  • Major payment and policy proposals related to cell and gene therapies
  • Other major proposals including new codes and payment rates applicable to ASTCT member physicians

There will be a Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar to info@astct.org. If you are unable to join, the recording will be made available. 

Please consider sharing this webinar with your network of doctors, administrators, providers, or any other colleagues that may be interested.